Dr. Gensheng Wang has been a leading scientist at Lovelace since 2009 and has led numerous preclinical drug development programs for small and large molecules and gene therapy products. He is an American board-certified Toxicologist and has over 10 years of experience in designing, conducting and reporting IND-enabling preclinical safety and biodistribution studies of potential new gene therapies.